Logo image of CNDA

CONCORD ACQUISITION CORP -A (CNDA) Stock Fundamental Analysis

NYSEARCA:CNDA - NYSE Arca - US20607U1088 - Common Stock - Currency: USD

10.5  0 (0%)

Fundamental Rating

1

Overall CNDA gets a fundamental rating of 1 out of 10. We evaluated CNDA against 0 industry peers in the Unkown industry. CNDA may be in some trouble as it scores bad on both profitability and health. CNDA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CNDA was profitable.
In the past year CNDA has reported a negative cash flow from operations.
CNDA Yearly Net Income VS EBIT VS OCF VS FCFCNDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 5M 10M

1.2 Ratios

Industry RankSector Rank
ROA 13.12%
ROE 23.37%
ROIC N/A
ROA(3y)3.62%
ROA(5y)N/A
ROE(3y)3.82%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNDA Yearly ROA, ROE, ROICCNDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 2 4

1.3 Margins

CNDA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNDA Yearly Profit, Operating, Gross MarginsCNDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for CNDA has been reduced compared to 1 year ago.
There is no outstanding debt for CNDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CNDA Yearly Shares OutstandingCNDA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 10M 20M 30M
CNDA Yearly Total Debt VS Total AssetsCNDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 11.82 indicates that CNDA is not in any danger for bankruptcy at the moment.
CNDA has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 11.82
ROIC/WACCN/A
WACCN/A
CNDA Yearly LT Debt VS Equity VS FCFCNDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M 100M 150M 200M 250M

2.3 Liquidity

CNDA has a Current Ratio of 0.15. This is a bad value and indicates that CNDA is not financially healthy enough and could expect problems in meeting its short term obligations.
A Quick Ratio of 0.15 indicates that CNDA may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.15
Quick Ratio 0.15
CNDA Yearly Current Assets VS Current LiabilitesCNDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 500K 1M 1.5M 2M 2.5M

More info and screens

0

3. Growth

3.1 Past

CNDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.85%.
EPS 1Y (TTM)-45.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 70.00 indicates a quite expensive valuation of CNDA.
The average S&P500 Price/Earnings ratio is at 28.98. CNDA is valued rather expensively when compared to this.
Industry RankSector Rank
PE 70
Fwd PE N/A
CNDA Price Earnings VS Forward Price EarningsCNDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNDA Per share dataCNDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CNDA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CONCORD ACQUISITION CORP -A

NYSEARCA:CNDA (8/30/2024, 8:04:01 PM)

10.5

0 (0%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)03-02 2024-03-02
Earnings (Next)N/A N/A
Inst Owners8.07%
Inst Owner Change-19.3%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap0
Analysts0
Price TargetN/A
Short Float %N/A
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 70
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 16.84
P/tB 16.84
EV/EBITDA N/A
EPS(TTM)0.15
EY1.43%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS0
BVpS0.62
TBVpS0.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 13.12%
ROE 23.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)3.62%
ROA(5y)N/A
ROE(3y)3.82%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.15
Quick Ratio 0.15
Altman-Z 11.82
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-45.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.51%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-124.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-74.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-74.85%
OCF growth 3YN/A
OCF growth 5YN/A